Recommendation of the President – Calquence (acalabrutinib)

On 10 September 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 95/2024 on the evaluation of the drug Calquence (acalabrutinib) under the drug program: Treatment of patients with chronic lymphocytic leukemia

Publication in Public Information Bulletin (BIP) >>